Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Sidney Kimmel Comprehensive Cancer Center Identifier:
First received: December 27, 2006
Last updated: May 15, 2013
Last verified: May 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2009
  Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)